Response to Correspondence on “Active Comparator-Controlled,Rater-Blinded Study of Corticotropin-Based Immunotherapies for Opsoclonus-Myoclonus Syndrome”
Restricted accessReview articleFirst published online March, 2013
Response to Correspondence on “Active Comparator-Controlled,Rater-Blinded Study of Corticotropin-Based Immunotherapies for Opsoclonus-Myoclonus Syndrome”
TateEDPranzatelliMRVerhulstSJ. Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome. J Child Neurol. 2012;27:875–884.
2.
PranzatelliMRTateEDDukartWSFlintMJHoffmanMTOksaAE. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr. 2005;147:372–378.
3.
BrunklausAPohlKZuberiSMde SousaC. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics. 2011;128:e388–e394.
4.
TateEDAllisonTJPranzatelliMRVerhulstSJ. Neuroepidemiologic trends in 105 U.S. cases of pediatric opsoclonus-myoclonus. J Pediatr Oncol Nurs. 2005;22:8–19.
5.
PranzatelliMRTateED. Opsoclonus-myoclonus syndrome. In: RussellCDVincentA, eds. Clinics in Developmental Medicine, No. 184-185: Inflammatory and Autoimmune Disorders of the Nervous System in Children. Cambridge, UK: Mac Keith Press; 2010: 152–173.
6.
PranzatelliMRTateEDSwanJA. B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord. 2010;25:238–242.
7.
PranzatelliMRTateEDTravelsteadALColliverJA. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus. J Clin Immunol. 2011;53:384–389.
PranzatelliMRTateEDHoefgenESwanJColliverJA. Therapeutic down-regulation of central and peripheral B-cell activating factor (BAFF) production in opsoclonus-myoclonus. Cytokine. 2008;44:26–32.
10.
PranzatelliMRTateEDMcGeeNR. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS. J Neuroimmunol. 2012;243:81–88.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
